Status and phase
Conditions
Treatments
About
In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated. In addition, the activity of the key enzymes related to HDL metabolism were assessed.
[ Designated as safety issue: No ]
In order to determine the relevance of the HDL increase in decreasing cardiovascular risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate marker for cardiovascular disease in patients.
[ Designated as safety issue: No ]
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients will be included when they meet the following criteria:
Exclusion criteria
Patients will not be included when they meet one or more of the following criteria:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal